- References (2)
- Inventor Info
|Antigen/Gene or Protein Targets||Ovarian cancer|
|Parental Line||Ascites of chemotherapy naive patient|
|Synonyms||HGSC, high grade mixed ovarian cancer, epithelial ovarian cancer|
|Disease Keywords||High Grade Ovarian Cancer|
|Relevance||Epithelial ovarian cancer is diagnosed at late disease stage in more than 70% of patients. Ovarian cancer is the leading cause of gynaecological cancer mortality worldwide with a 5-year overall survival of 30–39%. It has long been recognised by clinicians that ovarian cancer is a set of heterogeneous diseases. NUOC-1 cell line represents a novel ovarian cancer cell line derived from the ascites of a chemotherapy naïve patient with a primary mixed endometrioid/ clear cell/ high grade serous ovarian cancer|
|Production Details||Ascites were collected from patients undergoing surgery for ovarian cancer. 20 ml of ascites was added to 20 ml of warmed culture medium in T75 flask, and incubated at 37°C, 5% CO2, 95% humidified air. The medium was aspirated and 13 ml of warmed fresh medium was replaced on day 3 to 5. The medium was replaced every 4 to 5 days until the cells approached confluence|
|Research Area||Cancer, Drug Discovery & Development|
|Growth/Phenotype Keywords||Doubling time approximately 58 hours|
|Recommended Growing Conditions||RPMI 1640 medium supplemented with 20% FCS, 20 mM L-glutamine and 1% penicillin and streptomycin|
NUOC-1 cells grow as an adherent monolayer.
The cells are TP53 wildtype, positive for PTEN, HER2 and HER3 expression but negative for oestrogen, progesterone and androgen receptor expression.
NUOC-1 cells are competent in homologous recombination and non-homologous end joining, but base excision repair defective.
Karyotype analysis demonstrated a complex tetraploid karyotype
There are 2 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor